Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myelom...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 29; číslo 9; s. 1125
Hlavní autoři:	Henry, David H, Costa, Luis, Goldwasser, Francois, Hirsh, Vera, Hungria, Vania, Prausova, Jana, Scagliotti, Giorgio Vittorio, Sleeboom, Harm, Spencer, Andrew, Vadhan-Raj, Saroj, von Moos, Roger, Willenbacher, Wolfgang, Woll, Penella J, Wang, Jianming, Jiang, Qi, Jun, Susie, Dansey, Roger, Yeh, Howard
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.03.2011
Témata:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Density Conservation Agents - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - secondary Denosumab Diphosphonates - therapeutic use Double-Blind Method Female Humans Imidazoles - therapeutic use International Agencies Male Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - pathology Neoplasms - drug therapy Neoplasms - pathology RANK Ligand - therapeutic use Survival Rate Treatment Outcome Young Adult
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!